All Stories

  1. Associations among self-reported oral health and intrinsic capacity domains in U.S. older adults: analysis from NHANES 2009–2014
  2. Association between periodontal disease and intrinsic capacity in older adults: insights from NHANES 2009–2014
  3. The therapeutic potential of thalassotherapy for enhancing well-being and reducing pharmaceutical costs in individuals with disabilities
  4. Novel approaches for the treatment of frontotemporal dementia: is there hope for the future?
  5. Alzheimer's Disease May Benefit from Olive Oil Polyphenols: A Systematic Review on Preclinical Evidence Supporting the Effect of Oleocanthal on Amyloid-β Load
  6. Corrigendum to “Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence” [Biomed. Pharmacother. 188 (2025) 118199]
  7. Targeting oral frailty indicators of late-life cognitive disorders and depression: a systematic review
  8. Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: the challenges ahead
  9. The Effect of a Mediterranean Diet on Arterial Stiffness: A Systematic Review
  10. An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
  11. Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders
  12. The Biological Rationale for Integrating Intrinsic Capacity Into Frailty Models
  13. Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease
  14. Oral frailty indicators and cardio- and cerebrovascular diseases in older age: A systematic review
  15. Psychiatry and sensation: the epigenetic links
  16. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  17. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  18. Oral health indicators and bone mineral density disorders in older age: A systematic review
  19. Dietary Intake of Polyphenols and All-Cause Mortality: A Systematic Review with Meta-Analysis
  20. Social Dysfunction and Apathy: Transdiagnostic Domains in Late-Life Cognitive Disorders
  21. Impact of periodontal disease on cognitive disorders, dementia, and depression: a systematic review and meta-analysis
  22. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease
  23. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
  24. Multidimensional complex frailty phenotypes: epidemiological impact of oral frailty in older age
  25. Correction to: Ultra‑processed food consumption and nutritional frailty in older age
  26. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders
  27. The epigenetics of frailty
  28. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  29. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  30. Nutritional patterns as machine learning predictors of liver health in a population of elderly subjects
  31. The Relationship between Oral Health-Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  32. The Relationship between Oral Health‐Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  33. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders
  34. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies
  35. Exploring the Association of Burning Mouth Syndrome with Depressive and Anxiety Disorders in Middle-Aged and Older Adults: A Systematic Review
  36. Correction to: Dietary profiling of physical frailty in older age phenotypes using a machine learning approach: the Salus in Apulia Study
  37. Late-Onset Depression but not Early-Onset Depression may Increase the Risk of All-Cause Mortality in Older Age: 8-Year Follow-Up of the Salus in Apulia Study
  38. Processed foods and diet quality in pregnancy may affect child neurodevelopment disorders: a narrative review
  39. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies
  40. Associations of a biopsychosocial frailty phenotype with all-cause dementia, Alzheimer’s disease, vascular dementia, and other dementias: the Italian PRoject on the Epidemiology of Alzheimer’s disease (IPREA)
  41. Effect of Physical Activity Intervention on Gait Speed by Frailty Condition: A Randomized Clinical Trial
  42. Corrigendum: Dietary customs and social deprivation in an aging population from Southern Italy: A machine learning approach
  43. Corrigendum: Liver health and dementia in an Italian older population: Findings from the Salus in Apulia study
  44. Retinal Microvasculature and Neural Changes and Dietary Patterns in an Older Population in Southern Italy
  45. Effect of change of interleukin-6 over time on gait speed response: Results from the lifestyle interventions and independence for elders study
  46. Serum levels of IL-6 are associated with cognitive impairment in the salus in apulia population-based study
  47. Ultra-processed food consumption and nutritional frailty in older age
  48. Biopsychosocial frailty and mild cognitive impairment subtypes: Findings from the Italian project on the epidemiology of Alzheimer's disease (IPREA)
  49. Passive tau-based immunotherapy for tauopathies
  50. Temporomandibular Disorders as Contributors to Primary Headaches: A Systematic Review
  51. Dietary profiling of physical frailty in older age phenotypes using a machine learning approach: the Salus in Apulia Study
  52. Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study
  53. Apolipoprotein E genotype, inflammatory biomarkers, and non-psychiatric multimorbidity contribute to the suicidal ideation phenotype in older age. The Salus in Apulia Study
  54. Clinical Indicators of Oral Frailty: A Domain-Specific Frailty Phenotype
  55. Temporomandibular Disorders as a Risk Factor for Suicidal Behavior: A Systematic Review
  56. Oral frailty indicators to target major adverse health-related outcomes in older age: a systematic review
  57. The challenges of anti-tau therapeutics in Alzheimer disease
  58. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
  59. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
  60. Motoric Cognitive Risk Syndrome, Subtypes and 8-Year All-Cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  61. Motoric Cognitive Risk Syndrome, Subtypes and 8-year all-cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  62. Dietary Patterns Associated with Diabetes in an Older Population from Southern Italy Using an Unsupervised Learning Approach
  63. Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review
  64. Dietary Customs and Social Deprivation in an Aging Population From Southern Italy: A Machine Learning Approach
  65. Association of Neuroretinal Thinning and Microvascular Changes with Hypertension in an Older Population in Southern Italy
  66. Frailty and outcome after traumatic brain injury
  67. Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study
  68. The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy
  69. Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study
  70. Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
  71. Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study
  72. Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study
  73. Could Epigenetics Play a Role in Suicidal Behavior in Older Age?
  74. Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
  75. Beverages Consumption and Oral Health in the Aging Population: A Systematic Review
  76. How many frailties exist? – Authors' reply
  77. Associations between nutritional frailty and 8‐year all‐cause mortality in older adults: The Salus in Apulia Study
  78. COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy
  79. Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study
  80. Oral frailty and its determinants in older age: a systematic review
  81. Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides
  82. Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy
  83. Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy
  84. Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy
  85. Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study
  86. How gait influences frailty models and health‐related outcomes in clinical‐based and population‐based studies: a systematic review
  87. Vitamin D in the development and progression of alzheimer’s disease: implications for clinical management
  88. Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study
  89. Oral frailty and neurodegeneration in Alzheimer’s disease
  90. Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty
  91. Late-life depression and its impact on rehabilitation after traumatic injuries
  92. Social Frailty in the COVID-19 Pandemic Era
  93. A multidimensional frailty approach in predicting and preventing dementia
  94. Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy
  95. Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population
  96. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism
  97. Age-related hearing loss and neuropathologic burden
  98. The relationship between epigenetics and microbiota in neuropsychiatric diseases
  99. Age-related hearing loss and speech perception disorder: the broken interface between healthcare professionals and older adults
  100. Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
  101. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
  102. Can pharmacotherapy effectively reduce Alzheimer’s related agitation?
  103. Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy
  104. Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study
  105. The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase
  106. Social determinants of late-life depression epigenetics
  107. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
  108. Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study
  109. Corrigendum to “Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review” Neurosci. Biobehav. Rev. 95 (2018) 480–498
  110. The Challenge of Antidepressant Therapeutics in Alzheimer’s Disease
  111. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging
  112. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
  113. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline
  114. Time to test antibacterial therapy in Alzheimer’s disease
  115. Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia
  116. Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging
  117. The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear
  118. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
  119. Disease-modifying therapies for tauopathies: agents in the pipeline
  120. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
  121. Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer’s disease
  122. Understanding frailty to predict and prevent dementia
  123. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
  124. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke
  125. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
  126. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
  127. The Role of Biomarkers in Psychiatry
  128. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review
  129. Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life
  130. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
  131. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study
  132. CYP2D6 genotypes in revolving door patients with bipolar disorders
  133. Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review
  134. Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder
  135. Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention
  136. Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer’s Disease Versus Vascular Dementia
  137. Biopsychosocial Frailty and the Risk of Incident Dementia. The Italian Longitudinal Study of Aging
  138. Comprehensive Geriatric Assessment in Long-Term Care and Nursing Homes
  139. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging
  140. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
  141. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
  142. Cognitive frailty: a potential target for secondary prevention of dementia
  143. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry
  144. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review
  145. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline
  146. An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-term Care Facilities
  147. Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer’s Disease
  148. Emerging biomarkers and screening for cognitive frailty
  149. Genetics of tailored medicine: Focus on CNS drugs
  150. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging
  151. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association
  152. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?
  153. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
  154. The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes
  155. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
  156. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders
  157. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?
  158. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
  159. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?
  160. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder
  161. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?
  162. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
  163. Alternative pharmacological treatment options for agitation in Alzheimer’s disease
  164. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease
  165. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis
  166. Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients
  167. Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance